BioVie identifies two Long COVID patient groups with distinct responses to bezisterim
BioVie Inc. (BIVI, BIVIW) reported that its Long COVID trial identified two patient groups with distinct responses to its drug bezisterim. High-inflammatory patients showed cognitive improvements, while others improved in fatigue and post-exertional malaise. The trial, involving 203 participants, did not reach statistical significance overall. BioVie plans to present more data at an upcoming conference.
How this was made

The 30-second read
Why it matters
The subgroup findings provide a mechanistic rationale for targeted therapy but do not yet constitute a pivotal efficacy claim.
Market read
First‑time disclosure of biomarker‑driven subgroup efficacy may influence BioVie’s valuation and investor sentiment in the biotech sector.
What to watch
Future regulatory feedback and the need for larger confirmatory trials could delay or diminish commercial potential.
Background
BioVie is a clinical‑stage biotech focused on Long COVID treatments. The ADDRESS‑LC trial enrolled 203 participants to test bezisterim versus placebo.
Ticker impact
BioVie disclosed new biomarker subgroup results from its ADDRESS-LC Long COVID trial, the first public report of these findings.
modest upside as investors may price in subgroup efficacy while overall uncertainty tempers enthusiasm
Positive signals in defined subpopulations could drive speculative buying, but lack of statistical significance and safety parity with placebo limit upside.
Market effects
May spark broader interest in Long COVID therapeutics and biomarker‑driven trial designs within biotech.
Limited to U.S. biotech investors; no immediate regional effect.
Low global impact beyond niche biotech community.
Counterpoint
The lack of overall statistical significance suggests the results may not translate into commercial value, keeping the stock vulnerable to downside.
Key entities
- companyBioVie Inc
NASDAQ‑listed biotech developing bezisterim for Long COVID.
- institutionNational Institute of Allergy and Infectious Diseases
Co‑host of the RECOVER‑TLC workshop where data were presented.


